Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Yumanity Shares Fall On FDA Hold On Multidose Trials In Parkinson's Disease

The FDA has placed a partial clinical hold on Yumanity Therapeutics Inc's (NASDAQ:YMTX) multidose clinical trials of YTX-7739, currently being developed for Parkinson's disease.

  •  The FDA has not halted all clinical programming and permits the Company's planned single-dose clinical trial to proceed. 
  • The partial clinical hold suspends the initiation of multiple-dose clinical trials in the U.S. until the FDA's questions have been addressed.
  • Related: Yumanity Therapeutics Stock Plunges After Parkinson's Trial Data.
  • The Company expects to receive additional detail from the FDA within the next 30 days.
  • Related content: Benzinga's Full FDA Calendar.
  • YTX-7739 is Yumanity Therapeutics' proprietary lead small molecule investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target, stearoyl-CoA desaturase. 
  • Price Action: YMTX shares are down 20.4% at $1.95 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.